Evidence map›Paper›PMID 25818061›Full record

Trial reportDrug and alcohol dependence2015

Bupropion for the treatment of methamphetamine dependence in non-daily users: a randomized, double-blind, placebo-controlled trial.

Ann L Anderson, Shou-Hua Li, Denka Markova, Tyson H Holmes, Nora Chiang, Roberta Kahn, Jan Campbell, Daniel L Dickerson, Gantt P Galloway, William Haning and 3 more

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Drug and alcohol dependence, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00687713 (Phase 2, Double-Blind, Placebo-Controlled Trial of Bupropion for Methamphetamine Dependence), which is not on this map. Cited by 37 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 7 pooled it
6.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00687713 phase2completednot on this map

Phase 2, Double-Blind, Placebo-Controlled Trial of Bupropion for Methamphetamine Dependence

TypeinterventionalSponsorNational Institute on Drug Abuse (NIDA)Ran2008 to 2011Enrolled200ConditionsMethamphetamine DependenceArmsBupropion, Placebo
3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 7 syntheses or guidelines pooled it, 67 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Methamphetamine-Related Disorders.Deutsches Arzteblatt international · 2017
    Guideline
  6. Pooled it
  7. Guideline
  8. Trial
  9. Trial
  10. Trial
  11. Bupropion and Naltrexone in Methamphetamine Use Disorder.The New England journal of medicine · 2021
    Trial
  12. Randomized, Placebo-Controlled Trial of Targeting Neuroinflammation with Ibudilast to Treat Methamphetamine Use Disorder.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2020
    Trial
  13. Trial
  14. Trial
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 8 institutions in 1 country.

Ann L AndersonNational Institutes of Health, National Institute on Drug Abuse, Division of Pharmacotherapies and Medical Consequences, Bethesda, MD, USA. Electronic address: aa135m@nih.gov.
Shou-Hua LiNational Institutes of Health, National Institute on Drug Abuse, Division of Pharmacotherapies and Medical Consequences, Bethesda, MD, USA.
Denka MarkovaMedivation, Inc., San Francisco, CA, USA.
Tyson H HolmesStanford Center for Sleep Sciences and Medicine, Department of Psychiatry and Behavioral Sciences, School of Medicine, Stanford University, Stanford, CA, USA.
Nora ChiangNational Institutes of Health, National Institute on Drug Abuse, Division of Pharmacotherapies and Medical Consequences, Bethesda, MD, USA.
Roberta KahnNational Institutes of Health, National Institute on Drug Abuse, Division of Pharmacotherapies and Medical Consequences, Bethesda, MD, USA.
Jan CampbellUniversity of Kansas, Kansas City, KS, USA.
Daniel L DickersonIntegrated Substance Abuse Programs, University of California, Los Angeles, CA, USA.
Gantt P GallowaySt. Luke's Hospital, San Francisco, CA, USA.
William HaningUniversity of Hawaii, Honolulu, HI, USA.
John D RoacheUTX, Health Science Center, San Antonio, TX, USA.
Christopher StockVA Health Care System, Salt Lake City, UT, USA.
Ahmed M ElkashefNat'l Rehabilitation Center, Abu Dhabi, United Arab Emirates.
National Institutes of Health · USStanford University · USSt. Luke's Hospital · USThe University of Texas Health Science Center at San Antonio · USUniversity of California, Los Angeles · USUniversity of Hawaiʻi at Mānoa · USUniversity of Kansas · USVA Salt Lake City Healthcare System · US

Funding

Thalamic cortical dysfunction and predictors of relapse in cocaine dependenceK25DA040032 · NIDA · YALE UNIVERSITY · PI ZHANG, SHENG · 2015 to 2019
$834k
Intramural NIH HHS Z99 DA999999NIDA NIH HHS K25 DA040032NIDA NIH HHS N01 DA058857NIDA NIH HHS N01DA-05-8857
6 · The paper itself

Abstract

aimBupropion was tested for efficacy to achieve methamphetamine (MA) abstinence in dependent, non-daily users.

methodsA randomized, double-blind, placebo-controlled trial, with 12-week treatment and 4-week follow-up, was conducted with 204 treatment-seeking participants having MA dependence per DSM-IV, who used MA on a less-than-daily basis. 104 were randomized to matched placebo and 100 to bupropion, sustained-release 150mg, twice daily. Participants were seen three times weekly to obtain urine for MA and bupropion assays, study assessments, and thrice weekly, 90-min, group psychotherapy. There was no biomarker for placebo adherence. The primary outcome was achievement of abstinence throughout the last two weeks of treatment; 'success' requiring at least two urine samples during each of Weeks 11 and 12, and all samples MA-negative (<300ng/mL).

resultsBupropion and placebo groups did not differ significantly in the percentage achieving abstinence for the last 2 weeks of treatment (chi-square, p=0.32). Subgroup analysis of participants with lower baseline MA use (≤18 of last 30 days before consent) also revealed no difference in success between groups (p=0.73). Medication adherence per protocol (detectable bupropion, >5ng/mL, in ≥50% of urine samples from Study Weeks 1-10 and ≥66% of urine samples from Weeks 11 to 12) was achieved by 47% of participants taking bupropion.

conclusionsThese data indicate that bupropion did not increase abstinence in dependent participants who were using MA less-than-daily. Medication non-adherence was a limitation in this trial. Psychosocial therapy remains the mainstay of treatment for MA dependence. Further research on subgroups who may respond to bupropion may be warranted.

Indexed as

Psychotherapy, GroupAdultAmphetamine-Related DisordersBupropionDopamine Uptake InhibitorsDouble-Blind MethodFemaleHumansMaleMedication AdherenceMethamphetamineTreatment OutcomeBupropionDopamine Uptake InhibitorsMethamphetamineBupropionDrug therapyMedication adherenceMethamphetaminePatient acuitySubstance-related disorders

Identifiers

PMID25818061
PMCPMC4388163
OpenAlexW1979313563

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.